Is BioSante in line for a Big Pharma buyout?

BusinessWeek's Gene Marcial sized up BioSante Pharmaceutical's pipeline and concluded that its late stage therapy for sexual dysfunction in menopausal women could make it a prime candidate for a buyout. LibiGel began a second Phase III trial recently while data from the first late-stage efficacy study is due out in 2009.

In Marcial's view, BioSante is lining up for a piece of a multibillion-dollar market. And then BioSante did bring in Deutsche bank to assess its strategic alternatives--usually a dead giveaway that a good offer would receive welcoming smiles.

- read the column from BusinessWeek

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.